DoW Toxic Exposures Clinical Trial Award
Open Posted
- Opportunity number
- HT942526TERPCTA
- Agency
-
Medical Command
Department of the Army, Department of Defense
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Grant
- Category
-
- Science and Technology and other Research and Development
- Eligible applicants
-
- Unrestricted
- Points of contact
-
- eBRAP Help Desk help@ebrap.org (301) 682-5507
Opportunity details come from Grants.gov. Updated .
About this opportunity
The Department of the Army Medical Command is soliciting applications for the FY26 Toxic Exposures Research Program Clinical Trial Award to fund clinical trials addressing prevention, treatment, or management of military-related toxic exposures, with a full application deadline of November 19, 2026. The program expects to allocate approximately $4.5 million to fund one award capped at $4.5 million total cost with a maximum period of performance of four years.
Eligible applicants include extramural and intramural U.S. Department of War organizations, foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities. Independent investigators at all career levels may serve as Principal Investigator. The program offers an optional Partnering Principal Investigator arrangement in which two PIs collaborate with each PI receiving separate awards, intended to support interdisciplinary partnerships between clinicians and research scientists.
Proposed projects must address at least one FY26 TERP Program Goal (Predict and Prevent, Diagnose, or Treat) and at least one FY26 TERP Topic Area (Neurotoxin Exposure, Gulf War Illness and Its Treatment, Airborne Hazards and Burn Pits, or Other Military Service-Related Toxic Exposures). Projects may range from small proof-of-concept clinical trials (pilot, first-in-human, phase 0) through large-scale trials including pragmatic clinical trials. Applications require preliminary data supporting the proposed trial, detailed study designs demonstrating feasibility and access to study populations, statistical plans with power analysis, regulatory strategies, recruitment and retention plans, and post-award transition plans. The program requires clinical impact, military relevance, rigorous study design, inclusion of clinicians and military or Veteran consumers on research teams, recruitment of relevant military and Veteran populations, and compliance with STROBE, CONSORT, SPIRIT, and ARRIVE 2.0 guidelines.
Pre-applications are due August 19, 2026 at 5:00 p.m. Eastern Time; invitations to submit full applications will be issued by October 1, 2026. Awards will be made no later than September 30, 2027, using FY26 funds that expire for use on September 30, 2032. CFDA 12.420.
Synopsis
Summary: The fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Clinical Trial Award (CTA) mechanism supports the advancement, execution, and analysis of clinical trials with the potential to have a significant impact on the prevention, treatment, or management of symptoms, diseases or conditions associated with or resulting from military-related toxic exposures. Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) designed to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials (including pragmatic clinical trials) to determine efficacy in relevant patient populations.
Distinctive Features: To encourage applications that include meaningful and productive collaborations, the FY26 TERP CTA includes a Partnering Principal Investigator Option (PPIO). One Principal Investigator (PI) is identified as the initiating PI, and an additional PI may be identified as a Partnering PI. If recommended for funding, each PI will be named on separate awards. The intent is to support interdisciplinary partnerships, such as those between clinicians and research scientists, that will accelerate the movement of promising interventions/knowledge products into clinical applications. Partnering should significantly advance the research beyond what would be possible through independent efforts.
https://cdmrp.health.mil/pubs/press/2026/terppreann
Files
| File | Type | Posted |
|---|---|---|
| PKG00292894.pdf | ||
| HT942526TERPCTA_GG.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity